Rhenman & Partners Asset Management’s 10x Genomics TXG Stock Holding History

Rhenman & Partners Asset Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$326K	Buy	+8,500	New	+$223K	0.03%	97
2023 Q4	–	Sell	-68,000	Closed	-$2.81M	–	94
2023 Q3	$2.81M	Sell	68,000 -68,000	-50%	-$3.54M	0.3%	66
2023 Q2	$7.59M	Sell	136,000 -14,000	-9%	-$758K	0.8%	40
2023 Q1	$7.81M	Buy	150,000 +75,000	+100%	+$3.5M	0.86%	38
2022 Q4	$2.73M	Hold	75,000	–	–	0.29%	75
2022 Q3	$2.04M	Buy	+75,000	New	+$2.86M	0.21%	85

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rhenman & Partners Asset Management's TXG Position: Q2 2026 in Review

Rhenman & Partners Asset Management opened a new position in 10x Genomics (TXG) in Q2 2026: 8,500 shares worth $326K. The stake represents 0.03% of the portfolio and ranks #97 among its holdings. This is a return to the name: Rhenman & Partners Asset Management previously reported a position in TXG as recently as Q3 2023.

Rhenman & Partners Asset Management first reported a position in TXG in Q3 2022 and has held it in 6 quarters since. The position peaked at $7.81M in Q1 2023. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Rhenman & Partners Asset Management held 8,500 shares of 10x Genomics worth $326K as of Q2 2026.
10x Genomics was a new Rhenman & Partners Asset Management position in Q2 2026.
10x Genomics made up 0.03% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #97 holding.
Rhenman & Partners Asset Management first reported a position in 10x Genomics in Q3 2022 and has held it in 6 quarters since.
Rhenman & Partners Asset Management's 10x Genomics position peaked at $7.81M in Q1 2023.
393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.